Wen Yun, Yan Jian-Hua
The State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, Guangdong Province, China.
Int J Ophthalmol. 2019 Nov 18;12(11):1737-1745. doi: 10.18240/ijo.2019.11.12. eCollection 2019.
To report the effects of intravenous high-dose glucocorticoids (ivGC) and orbital decompression (OD) surgery for treatment of sight-threatening thyroid-associated ophthalmopathy (TAO).
A retrospective review of medical records from patients with sight-threatening TAO [definite or highly suspected dysthyroid optic neuropathy (DON)] treated with ivGC (60 cases) and OD (25 cases) was conducted at the Zhongshan Ophthalmic Center between January 2001 and January 2009. Patients were initially treated with ivGC (ivGC group). If no significant improvement in visual function was obtained, they then received OD surgery (OD group). The pre- versus post-treatment efficacies of either ivGC or OD in these patients were assessed using several indices, including visual acuity, intraocular pressure, ocular alignment, ocular motility, and exophthalmos.
Nighty-one eyes had definite DON while 79 were considered to have highly suspected DON. In the ivGC group, 51 individuals (85.0%) eventually demonstrated normal vision, while 10 patients (16.7%) demonstrated a reduction in deviation (<0.01), and 35 cases (58.3%) showed slight improvements in ocular motility (<0.01). In OD group, visual acuity improved in 24 cases (96.0%, <0.01) and all patients showed varying reductions of exophthalmos (mean: 4.35±1.13 mm, <0.01). Eight cases (32.0%) experienced an 8-15 PD reduction of deviation and ocular motility improved in 12 cases (48.0%), while 3 patients (12.0%) developed new-onset strabismus with diplopia post-surgically (<0.01). Patients were followed up at an average of 1.55±1.07y.
Both ivGC and OD show good therapeutic efficacy in the treatment of sight-threatening TAO. The presence of extremely poor eyesight (≥0.5logMAR) was corrected in some patients with ivGC alone, thus sparing these patients from subsequent OD surgery. In patients who were refractory to steroids, subsequent OD surgery often provided satisfactory outcomes, however, new-onset strabismus with diplopia was observed in 12.0% of these cases.
报告静脉注射大剂量糖皮质激素(ivGC)和眼眶减压(OD)手术治疗威胁视力的甲状腺相关性眼病(TAO)的效果。
对2001年1月至2009年1月在中山大学眼科中心接受ivGC治疗(60例)和OD手术(25例)的威胁视力的TAO患者[确诊或高度怀疑甲状腺功能障碍性视神经病变(DON)]的病历进行回顾性分析。患者最初接受ivGC治疗(ivGC组)。如果视觉功能没有明显改善,则接受OD手术(OD组)。使用包括视力、眼压、眼位、眼球运动和眼球突出度等多个指标评估ivGC或OD对这些患者治疗前后的疗效。
91只眼确诊为DON,79只眼被认为高度怀疑为DON。在ivGC组中,51例(85.0%)最终视力恢复正常,10例患者(16.7%)斜视度减小(<0.01),35例(58.3%)眼球运动略有改善(<0.01)。在OD组中,24例(96.0%,<0.01)视力改善,所有患者眼球突出度均有不同程度降低(平均:4.35±1.13mm,<0.01)。8例(32.0%)斜视度降低8-15棱镜度,12例(48.0%)眼球运动改善,3例(12.0%)术后出现新发斜视伴复视(<0.01)。患者平均随访1.55±1.07年。
ivGC和OD在治疗威胁视力的TAO方面均显示出良好的治疗效果。一些视力极差(≥0.5logMAR)的患者仅通过ivGC治疗视力得到矫正,从而避免了后续的OD手术。对于对类固醇难治的患者,后续的OD手术通常能取得满意的效果,然而,这些病例中有12.0%出现了新发斜视伴复视。